November 5, 2026

BSE Limited
The Listing Department
Phiroze Jeejeebhoy Towers
25th Floor, Dalal Street
Fort, Mumbai 400 001
Maharashtra, India
BSE Scrip Code: **544309**

National Stock Exchange of India Limited
The Listing Department
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (East), Mumbai 400051
Maharashtra, India
NSE Symbol: **IKS**

Dear Sir/Ma'am,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Outcome of the Board Meeting held on November 5, 2026.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (**"SEBI LODR Regulations"**), we hereby inform that the Board of Directors of Inventurus Knowledge Solutions Limited (**"the Company"**) at its meeting held today, i.e., November 5, 2026, *inter alia*, considered and approved the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended September 30, 2026 ("**Financial Results**").

The Financial Results and Limited Review Report issued by Price Waterhouse Chartered Accountants LLP, Statutory Auditors of the Company on the said Financial Results are enclosed.

The Board Meeting commenced at 07:35 P.M. IST and concluded at 08:36 P.M. IST.

The aforementioned information is also available on the Company's website at https://ikshealth.com/investor-relations/.

Kindly take the above information on record.

Yours sincerely,
For **Inventurus Knowledge Solutions Limited**

Sameer S Chavan
Digitally signed by Sameer S Chavan
Date: 2026.11.05 21:43:32 +05'30'

Sameer Chavan
Company Secretary and Compliance Officer
Membership No. F7211

Encl: As above

Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
Inventurus Knowledge Solutions Limited
Building No. 5 & 6, Unit No. 801,
8th Floor, Mindspace SEZ, Thane Belapur Road,
Airoli, Navi Mumbai, Thane, Maharashtra 400708

1. We have reviewed the standalone unaudited financial results of Inventurus Knowledge Solutions Limited (the "Company") for the quarter ended September 30, 2026 and the year to date results for the period April 1, 2026 to September 30, 2026, the Standalone Unaudited Statement of Assets and Liabilities as on that date and the Standalone Unaudited Statement of Cash Flows for the half year ended on that date which are included in the accompanying 'Statement of unaudited financial results for the quarter and half year ended September 30, 2026' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been digitally signed by us for identification purposes.

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016

ALI AKBAR
Digitally signed by ALI AKBAR
Date: 2026.11.05 21:05:48 +05'30'

Ali Akbar
Partner
Membership Number: 117839
UDIN: 26117839PZYZGJ7223

Place: Mumbai
Date: November 5, 2026

Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
Inventurus Knowledge Solutions Limited
Building No. 5 & 6, Unit No. 801,
8th Floor, Mindspace SEZ, Thane Belapur Road,
Airoli, Navi Mumbai, Thane, Maharashtra 400708

1. We have reviewed the consolidated unaudited financial results of Inventurus Knowledge Solutions Limited (the "Holding Company"), its subsidiaries (the Holding Company and its subsidiaries hereinafter referred to as the "Group"), and its share of the net loss after tax and total comprehensive loss of its associate company (refer paragraph 4 below) for the quarter ended September 30, 2026 and the year to date results for the period April 1, 2026 to September 30, 2026, the Consolidated Unaudited Statement of Assets and Liabilities as on that date and the Consolidated Unaudited Statement of Cash Flows for the half year ended on that date which are included in the accompanying 'Statement of unaudited financial results for the quarter and half year ended September 30, 2026' (the "Statement"). The Statement is being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been digitally signed by us for identification purposes.

2. This Statement, which is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the Holding Company and following entities:

Relationship	Entity name
Wholly owned Subsidiaries	Inventurus Knowledge Solutions Inc IKS Cares Foundations ARAI Solutions Private Limited
Step Down Subsidiaries	Aquity Holdings, Inc Aquity Solutions, LLC Aquity Solutions India Private Limited Aquity Canada ULC Aquity Solutions Australia Pty Ltd. IKS WWMG MSO, LLC [with effect from June 30, 2026] Value Partners Collective ACO, LLC TruBridge Inc. Healthcare Resource Group, Inc iNetXperts, Corp. d/b/a Get Real Health Healthland Holding Inc. Healthland, Inc TruBridge Healthcare Private Limited IKS Next Horizon Inc (merged with TruBridge Inc. w.e.f July 9, 2026)
Associate	IKS WWMG MSO, LLC [up to June 29, 2026]

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraphs 6 (a) and 6 (b) below, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. (a) The interim consolidated financial information of one step down subsidiary (including its 5 subsidiaries) reflect total assets of Rs. 36,221.65 million and net assets of Rs. 29,956.74 million as at September 30, 2026 and total revenue from operations of Rs. 7,442.11 million, profit after tax of Rs. 1,006.38 million and total comprehensive income of Rs. 1,082.92 million, for the period from July 9, 2026 (date of acquisition) to September 30, 2026, and cash flows (net) of Rs. 1,335.41 million for the period from July 9, 2026 (date of acquisition) to September 30, 2026, as considered in the Statement. This interim financial information has been reviewed by other auditors in accordance with SRE 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" and their report, vide which they have issued an unmodified conclusion, has been furnished to us by the Holding Company's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

(b) The interim financial information of one step down subsidiary reflect total assets of Rs. 2,569.12 million and net assets of Rs. 2,043.20 million as at September 30, 2026 and total revenue from operations of Rs. 362.74 million and Rs. 790.49 million, profit after tax of Rs. 70.49 million and Rs. 123.25 million, and total comprehensive income of Rs. 69.97 million and Rs. 128.75 million for the quarter ended and for the period from April 1, 2026 to September 30, 2026, respectively, and cash flows

(net) of Rs. 202.49 million for the period from April 1, 2026 to September 30, 2026, as considered in the Statement. This interim financial information has been reviewed by other auditors in accordance with SRE 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" and their report, vide which they have issued an unmodified conclusion, has been furnished to us by the Holding Company's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

7. The consolidated unaudited financial results include the interim financial information of four subsidiaries (including one subsidiary with effect from June 30, 2026), which have not been reviewed by their auditors, whose interim financial information reflect total assets of Rs. 2,093.13 million and net assets of Rs. 1,706.54 million as at September 30, 2026 and total revenue from operations of Rs. 1,088.90 million and Rs. 1,089.18 million , loss after tax of Rs. 116.09 million and Rs. 121.76 million and total comprehensive loss of Rs. 95.45 million and Rs. 101.12 million for the quarter ended September 30, 2026 and for the period from April 1, 2026 to September 30, 2026, respectively, and cash flows (net) of Rs. 2.29 million for the period from April 1, 2026 to September 30, 2026, as considered in the consolidated unaudited financial results. The consolidated unaudited financial results also include the Group's share of loss after tax of Rs. 53.07 million and total comprehensive loss of Rs. 53.07 million for the period from April 1, 2026 to June 29, 2026, as considered in the consolidated unaudited financial results, in respect of one associate based on their interim financial information, which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016

ALI AKBAR
Digitally signed by ALI AKBAR
Date: 2026.11.05 21:06:27 +05'30'

Ali Akbar
Partner
Membership Number: 117839
UDIN: 26117839WWQXUK9733

Place: Mumbai
Date: November 5, 2026

Inventurus Knowledge Solutions Limited
Registered office : 801, Building No 5&6 8th floor, Mindspace Business Park (SEZ),
Thane Belapur Road, Airoli, Navi Mumbai - 400 708, Thane, Maharashtra, India.
CIN - L72200MH2006PLC337651 Telephone : +91 22 3964 3205
Website: www.ikshealth.com Email: : investor_relations@ikshealth.com

Statement of unaudited financial results for the quarter and half year ended September 30, 2026

(Amounts in INR/₹ Million, unless otherwise stated)

Sr.No	Particulars	Consolidated						Standalone					
		For the Quarter ended			For the Half Year ended		For the Year ended	For the Quarter ended			For the Half Year ended		For the Year ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
		unaudited	unaudited	unaudited	unaudited	unaudited	audited	unaudited	unaudited	unaudited	unaudited	unaudited	audited
1	**INCOME**												
	Revenue from operations	15,924.78	8,936.29	7,810.91	24,861.07	15,211.86	31,937.88	3,788.65	4,752.68	3,556.91	8,541.33	6,751.60	14,913.79
	Other income	233.82	57.10	36.55	290.92	67.68	171.94	70.61	14.57	16.75	85.18	38.24	71.58
	Total income	**16,158.60**	**8,993.39**	**7,847.46**	**25,151.99**	**15,279.54**	**32,109.82**	**3,859.26**	**4,767.25**	**3,573.66**	**8,626.51**	**6,789.84**	**14,985.37**
2	**EXPENSES**												
	Changes in inventories of stock-in-trade	22.45	(1.62)	-	20.83	-	13.91	-	-	-	-	-	-
	Employee benefit expenses	8,036.47	4,550.10	4,070.50	12,586.57	8,030.12	16,272.84	1,919.57	1,984.90	1,491.04	3,904.47	2,919.37	6,323.83
	Finance cost	1,019.15	101.10	161.49	1,120.25	342.28	702.48	40.17	35.77	24.58	75.94	51.80	121.75
	Depreciation and amortisation expenses	897.90	342.89	301.43	1,240.79	580.46	1,241.50	109.94	109.29	91.22	219.23	164.29	373.39
	Other expenses	3,450.57	1,438.41	1,022.78	4,888.98	2,086.60	4,737.72	554.71	573.57	287.11	1,128.28	556.23	1,236.06
	Total expenses	**13,426.54**	**6,430.88**	**5,556.20**	**19,857.42**	**11,039.46**	**22,968.45**	**2,624.39**	**2,703.53**	**1,893.95**	**5,327.92**	**3,691.69**	**8,055.03**
3	**Profit before share of profit/(loss) from associates and tax (1-2)**	**2,732.06**	**2,562.51**	**2,291.26**	**5,294.57**	**4,240.08**	**9,141.37**	**1,234.87**	**2,063.72**	**1,679.71**	**3,298.59**	**3,098.15**	**6,930.34**
4	Share of profit/(loss) from associates accounted for using the equity method (net of tax)	-	(53.07)	(14.18)	(53.07)	(14.18)	(92.22)	-	-	-	-	-	-
5	**Profit before tax (3+4)**	**2,732.06**	**2,509.44**	**2,277.08**	**5,241.50**	**4,225.90**	**9,049.15**	**1,234.87**	**2,063.72**	**1,679.71**	**3,298.59**	**3,098.15**	**6,930.34**
6	**Tax Expenses**												
	Current tax	560.95	682.98	615.45	1,243.93	1,187.65	2,003.69	205.37	502.26	293.47	707.63	539.38	1,249.26
	Deferred tax	37.40	(110.95)	(145.56)	(73.55)	(284.33)	(170.08)	66.83	(64.00)	2.25	2.83	46.03	15.89
	Total tax Expenses	**598.35**	**572.03**	**469.89**	**1,170.38**	**903.32**	**1,833.61**	**272.20**	**438.26**	**295.72**	**710.46**	**585.41**	**1,265.15**
7	**Profit for the period / year (5-6)**	**2,133.71**	**1,937.41**	**1,807.19**	**4,071.12**	**3,322.58**	**7,215.54**	**962.67**	**1,625.46**	**1,383.99**	**2,588.13**	**2,512.74**	**5,665.19**

The statutory auditor has digitally signed the statement for identification purpose only and this statement should be read in conjuction with their report dated November 5, 2026.

Inventurus Knowledge Solutions Limited
Registered office : 801, Building No 5&6 8th floor, Mindspace Business Park (SEZ),
Thane Belapur Road, Airoli, Navi Mumbai - 400 708, Thane, Maharashtra, India.
CIN - L72200MH2006PLC337651 Telephone : +91 22 3964 3205
Website: www.ikshealth.com Email: : investor_relations@ikshealth.com

Statement of unaudited financial results for the quarter and half year ended September 30, 2026

(Amounts in INR/₹ Million, unless otherwise stated)

Sr.No	Particulars	Consolidated						Standalone					
		For the Quarter ended			For the Half Year ended		For the Year ended	For the Quarter ended			For the Half Year ended		For the Year ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
		unaudited	unaudited	unaudited	unaudited	unaudited	audited	unaudited	unaudited	unaudited	unaudited	unaudited	audited
8	**Profit/(loss) for the period / year attributable to:**												
	Owners of the company	**2,176.48**	**1,937.41**	**1,807.19**	**4,113.89**	**3,322.58**	**7,215.54**	**-**	**-**	**-**	**-**	**-**	**-**
	Non-controlling interests	**(42.77)**	**-**	**-**	**(42.77)**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
9	**Other Comprehensive Income**												
	Items that may be reclassified to profit or loss												
	Gains/ (losses) on cash flow hedges (net)	151.31	359.93	(372.89)	511.24	(304.85)	(856.30)	151.31	359.93	(351.41)	511.24	(293.63)	(855.10)
	Exchange differences on translation of financial statements of foreign operations	242.37	(0.50)	495.43	241.87	515.01	1,617.53	-	-	-	-	-	-
	Income tax relating to above items	(31.24)	(75.58)	78.85	(106.82)	64.01	178.37	(31.24)	(75.58)	73.75	(106.82)	61.49	178.37
		362.44	**283.85**	**201.39**	**646.29**	**274.17**	**939.60**	**120.07**	**284.35**	**(277.66)**	**404.42**	**(232.14)**	**(676.73)**
	Items that will not be reclassified to profit or loss												
	Remeasurement of post employment benefit obligations	(8.14)	8.91	(21.21)	0.77	(35.46)	(31.55)	(8.52)	4.10	(13.02)	(4.42)	(21.57)	(20.01)
	Changes in the fair value of equity investments at FVOCI	**-**	226.42	931.52	226.42	931.52	931.52	-	-	-	-	-	-
	Income tax relating to above items	(0.70)	(56.86)	(240.67)	(57.56)	(236.92)	(206.53)	2.35	(0.96)	3.49	1.39	5.81	5.36
		(8.84)	**178.47**	**669.64**	**169.63**	**659.14**	**693.44**	**(6.17)**	**3.14**	**(9.53)**	**(3.03)**	**(15.76)**	**(14.65)**
	Other Comprehensive Income / (loss) for the period / year, net of tax	**353.60**	**462.32**	**871.03**	**815.92**	**933.31**	**1,633.04**	**113.90**	**287.49**	**(287.19)**	**401.39**	**(247.90)**	**(691.38)**
10	**Other comprehensive income attributable to:**												
	Owners of the company	**344.21**	**462.32**	**871.03**	**806.53**	**933.31**	**1,633.04**	**-**	**-**	**-**	**-**	**-**	**-**
	Non-controlling interests	**9.39**	**-**	**-**	**9.39**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
11	**Total Comprehensive Income for the period / year (7+9)**	**2,487.31**	**2,399.73**	**2,678.22**	**4,887.04**	**4,255.89**	**8,848.58**	**1,076.57**	**1,912.95**	**1,096.80**	**2,989.52**	**2,264.84**	**4,973.81**
12	**Total comprehensive income/ (loss) attributable to:**												
	Owners of the company	**2,520.69**	**2,399.73**	**2,678.22**	**4,920.42**	**4,255.89**	**8,848.58**	**-**	**-**	**-**	**-**	**-**	**-**
	Non-controlling interests	**(33.38)**	**-**	**-**	**(33.38)**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
13	**Paid-up equity share capital (Face value ₹ 1 per share)**	**170.91**	**170.85**	**170.44**	**170.91**	**170.44**	**170.71**	**170.91**	**170.85**	**170.44**	**170.91**	**170.44**	**170.71**
14	**Reserves excluding revaluation reserves as at balance sheet date**				**33,234.17**	**22,237.92**	**27,831.66**				**21,185.32**	**14,620.23**	**17,713.67**
15	**Earnings per share (Nominal value of share ₹ 1 each)**												
	Basic (INR per share)	**12.98**	**11.56**	**10.81**	**24.54**	**19.88**	**43.12**	**5.74**	**9.70**	**8.28**	**15.44**	**15.03**	**33.85**
	Diluted (INR per share)	**12.72**	**11.32**	**10.58**	**24.04**	**19.44**	**42.26**	**5.63**	**9.50**	**8.08**	**15.13**	**14.70**	**33.18**

The statutory auditor has digitally signed the statement for identification purpose only and this statement should be read in conjuction with their report dated November 5, 2026.

Inventurus Knowledge Solutions Limited
Registered office : 801, Building No 5&6 8th floor, Mindspace Business Park (SEZ),
Thane Belapur Road, Airoli, Navi Mumbai - 400 708, Thane, Maharashtra, India.
CIN - L72200MH2006PLC337651 Telephone : +91 22 3964 3205
Website: www.ikshealth.com Email: : investor_relations@ikshealth.com

Statement of Assets and Liabilities

(Amounts in INR/₹ Million, unless otherwise stated)

	Consolidated		Standalone	
	As at September 30, 2026	As at March 31, 2026	As at September 30, 2026	As at March 31, 2026
	unaudited	Audited	unaudited	Audited
A ASSETS				
Non-current assets				
Property, plant and equipment	746.88	540.68	372.27	433.78
Capital work-in-progress	3.20	-	3.19	-
Right-of-use assets	1,279.77	924.23	732.19	815.35
Goodwill	52,357.96	13,258.42	-	-
Other intangible assets	23,782.41	4,699.42	162.49	211.95
Intangible assets under development	61.68	61.33	61.69	34.92
Financial assets				
Investments	52.23	1,567.85	13,933.82	13,521.99
Loans	261.66	235.93	-	-
Trade receivables	1,619.48	1,931.45	57.58	558.44
Other financial assets	3,025.20	2,917.44	99.51	95.95
Non-current tax assets (net)	1,079.13	687.63	34.23	60.61
Deferred tax assets (net)	2,174.99	1,892.51	1,170.98	1,279.23
Other non-current assets	1,176.80	865.49	71.59	40.47
Total non-current assets	**87,621.39**	**29,582.38**	**16,699.54**	**17,052.69**
Current assets				
Inventories	26.06	0.58	-	-
Financial assets				
Investments	1,522.63	2,201.02	-	-
Trade receivables	11,478.28	5,644.82	8,190.89	3,963.94
Cash and cash equivalents	5,285.38	3,887.16	432.67	273.16
Other bank balances	1.38	1.38	1.30	1.29
Loans	1,741.45	-	-	-
Other financial assets	1,037.17	828.80	72.55	116.64
Contract assets	77.25	19.62	1.56	15.24
Other current assets	1,147.95	513.05	108.66	216.59
Total current assets	**22,317.55**	**13,096.43**	**8,807.63**	**4,586.86**
TOTAL ASSETS	**109,938.94**	**42,678.81**	**25,507.17**	**21,639.55**
B EQUITY AND LIABILITIES				
Equity				
Equity share capital	170.91	170.71	170.91	170.71
Other equity	33,234.17	27,831.66	21,185.32	17,713.67
Equity attributable to owners	**33,405.08**	**28,002.37**	**21,356.23**	**17,884.38**
Non-controlling interests	717.79	-	-	-
Total equity	**34,122.87**	**28,002.37**	**21,356.23**	**17,884.38**
Liabilities				
Non-current liabilities				
Financial liabilities				
Borrowings	57,523.39	2,749.90	-	-
Lease liabilities	1,150.20	789.14	659.71	741.44
Deferred tax liabilities (net)	2,797.85	1,102.90	-	-
Provisions	339.12	333.98	237.17	202.95
Total non-current liabilities	**61,810.56**	**4,975.92**	**896.88**	**944.39**
Current liabilities				
Financial liabilities				
Borrowings	579.85	3,656.77	478.54	106.59
Lease liabilities	331.65	329.34	260.46	254.65
Trade payables				
a) total outstanding dues of micro enterprises and small enterprises	26.58	30.13	24.54	26.53
b) total outstanding dues other than micro enterprises and small enterprises	2,950.93	1,456.92	752.06	444.17
Other financial liabilities	778.13	992.96	482.94	973.85
Contract liabilities	1,014.67	128.40	0.56	1.17
Provisions	3,441.57	644.09	198.63	171.28
Current tax liabilities (net)	667.71	554.61	0.19	0.19
Other current liabilities	4,214.42	1,907.30	1,056.14	832.35
Total current liabilities	**14,005.51**	**9,700.52**	**3,254.06**	**2,810.78**
TOTAL LIABILITIES	**75,816.07**	**14,676.44**	**4,150.94**	**3,755.17**
TOTAL EQUITY AND LIABILITIES	**109,938.94**	**42,678.81**	**25,507.17**	**21,639.55**

Inventurus Knowledge Solutions Limited
Registered office : 801, Building No 5&6 8th floor, Mindspace Business Park (SEZ),
Thane Belapur Road, Airoli, Navi Mumbai - 400 708, Thane, Maharashtra, India.
CIN - L72200MH2006PLC337651 Telephone : +91 22 3964 3205
Website: www.ikshealth.com Email: : investor_relations@ikshealth.com

Statement of Cash Flows

(Amounts in INR/₹ Million, unless otherwise stated)

	Particulars	Consolidated		Standalone	
		For the six months period ended September 30, 2026	For the six months period ended September 30, 2025	For the six months period ended September 30, 2026	For the six months period ended September 30, 2025
		unaudited	unaudited	unaudited	unaudited
(A)	**Cash flows from operating activities**				
	Profit before tax	5,294.57	4,240.08	3,298.59	3,098.15
	Adjustment for:				
	Depreciation and amortisation	1,240.79	580.46	219.23	164.29
	Finance Cost	1,120.25	342.26	75.94	71.74
	Interest income	(123.57)	(60.55)	(6.72)	(16.93)
	Fair value of investment in associate	(145.85)	-	-	-
	Loss allowance on trade receivables	-	30.30	-	30.30
	Profit on Sale / Discard of Property, plant and equipment	(2.26)	(2.28)	(1.09)	(0.53)
	Gain on lease cancellation	(11.61)	-	-	-
	Share based compensation expenses	393.54	184.72	91.72	88.33
	Fair value changes in derivatives	119.50	43.97	119.50	43.97
	Unwinding of discount on security deposit	(4.53)	(4.27)	(3.36)	(2.95)
	Unrealised Exchange rate fluctuations loss / (gain), net	87.12	(180.55)	5.93	(121.40)
	Change in operating assets and liabilities				
	(Increase)/Decrease in trade receivable	(3,558.67)	(636.69)	(3,740.23)	(2,214.58)
	Increase/(Decrease) in trade payable	(680.47)	58.84	314.39	197.44
	(Increase)/Decrease in inventories	(25.82)	-	-	-
	(Increase)/Decrease in other financial assets and liabilities	89.98	(484.62)	(58.62)	38.49
	(Increase)/Decrease in contract assets	27.20	(29.86)	13.68	(21.50)
	(Increase)/Decrease in other non-current assets	8.49	20.49	(36.81)	7.52
	(Increase)/Decrease in other current assets	(220.10)	(91.58)	107.92	(2.67)
	Increase/(Decrease) in provisions	40.05	13.02	57.15	21.64
	Increase/(Decrease) in contract liabilities	(249.30)	15.93	(0.61)	(0.49)
	Increase/(Decrease) in other current liabilities	143.79	680.29	223.85	268.02
	Cash generated from operations	**3,543.10**	**4,719.96**	**680.46**	**1,648.84**
	Income taxes paid	(1,317.80)	(735.16)	(681.24)	(439.91)
	Net cash flow from/(used in) operating activities (A)	**2,225.30**	**3,984.80**	**(0.78)**	**1,208.93**
(B)	**Cash flow from investing activities**				
	Payment for acquisition of subsidiary, net of cash acquired	(51,314.81)	-	(110.00)	-
	Payments for property, plant and equipment	(31.58)	(80.01)	(22.13)	(71.72)
	Payment for intangible assets	(219.76)	(126.39)	(18.07)	(107.37)
	Proceeds from sale of investments	931.93	-	-	-
	Proceeds from maturity of term deposits	-	50.53	-	50.53
	Payments for investment in subsidiary	-	-	-	(1,234.92)
	Investment in associates	-	(1,455.54)	-	-
	Loan given	(204.82)	(190.90)	-	-
	Loan to related party	-	-	-	(50.00)
	Repayment of loan by related party	-	-	-	227.90
	Proceeds from sale of property, plant and equipment	2.54	1.78	1.09	0.57
	Interest received	13.94	31.69	0.87	21.99
	Net cash flow from/(used in) investing activities (B)	**(50,822.56)**	**(1,768.84)**	**(148.24)**	**(1,163.02)**

Inventurus Knowledge Solutions Limited
Registered office : 801, Building No 5&6 8th floor, Mindspace Business Park (SEZ),
Thane Belapur Road, Airoli, Navi Mumbai - 400 708, Thane, Maharashtra, India.
CIN - L72200MH2006PLC337651 Telephone : +91 22 3964 3205
Website: www.ikshealth.com Email: : investor_relations@ikshealth.com

Statement of Cash Flows

(Amounts in INR/₹ Million, unless otherwise stated)

	Particulars	Consolidated		Standalone	
		For the six months period ended September 30, 2026	For the six months period ended September 30, 2025	For the six months period ended September 30, 2026	For the six months period ended September 30, 2025
		unaudited	unaudited	unaudited	unaudited
(C)	**Cash flow from financing activities**				
	Proceeds from issue of shares and share application money	88.74	62.75	88.74	62.75
	Proceeds/(repayment) of working capital loan	-	(341.51)	470.00	-
	Proceeds from borrowings	56,981.12	-	-	-
	Repayment of borrowings	(4,370.62)	(1,054.62)	-	-
	Payment for principal element of lease liabilities	(164.12)	(104.43)	(75.92)	(45.20)
	Payment for interest element of lease liabilities	(60.08)	(51.72)	(48.93)	(43.81)
	Interest paid	(435.29)	(329.22)	(18.47)	(7.98)
	Net cash flow from/(used in) financing activities (C)	**52,039.75**	**(1,818.75)**	**415.42**	**(34.24)**
(D)	Net increase/(decrease) in cash and cash equivalents (A+B+C)	3,442.49	397.21	266.40	11.67
	Cash and cash equivalents at the beginning of the period	1,854.46	1,804.22	166.57	731.16
	Effect of exchange differences on balances with banks in foreign currency	(11.57)	34.89	(0.30)	5.16
	Cash and cash equivalents at the end of the period	**5,285.38**	**2,236.32**	**432.67**	**747.99**
	Non-cash financing and investing activities				
	Acquisition of right-of-use assets	-	341.74	-	341.74
	Issue of equity shares against share application money	-	0.21	-	0.21
	Reconciliation of cash and cash equivalents				
	Components of cash and cash equivalents				
	Cash on hand	0.13	1.17	0.09	0.91
	Balances with banks:				
	Current accounts	5,095.11	1,802.13	242.44	384.11
	Remittances in transit	-	42.77	-	42.77
	Deposit account	190.14	390.25	190.14	320.20
	Cash and cash equivalents	**5,285.38**	**2,236.32**	**432.67**	**747.99**
	Working capital loan	-	-	-	-
	Cash and cash equivalents in cash flow statement	**5,285.38**	**2,236.32**	**432.67**	**747.99**

Inventurus Knowledge Solutions Limited
Registered office : 801, Building No 5&6 8th floor, Mindspace Business Park (SEZ),
Thane Belapur Road, Airoli, Navi Mumbai - 400 708, Thane, Maharashtra, India.
CIN - L72200MH2006PLC337651 Telephone : +91 22 3964 3205
Website: www.ikshealth.com Email: : investor_relations@ikshealth.com

Notes to the Statement of Unaudited Consolidated and Standalone Financial Results for the quarter and half year ended September 30, 2026

1 The above standalone financial results of Inventurus Knowledge Solutions Limited ("the Company") and consolidated financial results of the Company and its subsidiaries (collectively "the Group") and its interest in associate for the quarter and half year ended September 30, 2026 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on November 05, 2026. The above results for the quarter and half year ended September 30, 2026 have been reviewed by the Statutory Auditors of the Company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

2 The statement has been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder.

3 The Group operates in one reportable business segment which comprises a Care enablement platform providing technology enabled solutions to Healthcare providers. This in the context of Indian Accounting Standard (Ind AS 108) "Operating Segments", constitutes a single operating segment.

4 The Company has allotted 60,071 shares for the quarter ended September 30, 2026 (quarter ended September 30, 2025 : 183,140 shares) and 200,156 shares for the half year ended September 30, 2026 (half year ended September 30, 2025 : 207,082) to eligible employees on exercise of Employee Stock options, in accordance with the terms and conditions of the IKS Employees Stock Options Plan 2022 named 'IKS Health - ESOP Policy 2022' as approved by the shareholders of the Company on April 22, 2022. Further, during the quarter and half year ended September 30, 2026, the Company has granted 61,000 and 204,814 stock options respectively to eligible employees, as approved by the Nomination and Remuneration Committee.

5 Earnings per share for the interim periods are not annualised.

6 The consolidated financial results of the Group include the results of its subsidiary companies viz: Inventurus Knowledge Solutions Inc ("IKS Inc."), IKS Cares Foundation, ARAI Solutions Private Limited and its step down subsidiary companies viz: Aquity Holdings Inc, Aquity Solutions LLC, Aquity Solutions India Private Limited, Aquity Solutions Australia Pty Limited, Aquity Canada ULC, TruBridge, Inc and its subsidiaries namely, Healthcare Resource Group, Inc, iNetXperts, Corp. d/b/a Get Real Health, Healthland Holding Inc., Healthland, Inc and TruBridge Healthcare Private Limited (w.e.f. July 9, 2026), IKS WWMG MSO LLC (subsidiary w.e.f. June 30, 2026 and associate upto June 29, 2026) and Value Partners Collective ACO, LLC. IKS Next Horizon, Inc (merged with TruBridge Inc w.e.f July 9,2026).

7 TruBridge, Inc. ("TruBridge") acquisition was completed by Inventurus Knowledge Solutions Limited ("IKS" or "the Group"), through its wholly-owned subsidiary, on July 9, 2026, following which its shares were delisted from Nasdaq. TruBridge provides electronic health record (EHR) and revenue cycle management (RCM) solutions to rural and community hospitals in the United States. The acquisition was priced at an Enterprise Value of USD 557.0 million, at USD 26.25 per share payable to the TruBridge's selling shareholders and the fully diluted equity outstanding as of the acquisition date. The transaction was financed through debt facilities. The acquisition integrates the Group's ambulatory care enablement capabilities with TruBridge's acute-care EHR and RCM platform. TruBridge has been consolidated in the Group's financial statements effective July 9, 2026.The excess of purchase consideration over net assets has been provisionally recognised as goodwill amounting to $394.97 million (₹ 37,670.43 million) after recognition of intangible assets arising on account of acquisition. The purchase price allocation is provisional pending finalization of adjustments within 12 months from acquisition date as allowed under Ind-AS 103.

8 During the period ended September 30, 2026, IKS Inc. acquired an additional 6.29% equity stake in IKS WWMG MSO LLC for ₹478.97 million in cash increasing its total stake from 48.20% to 54.49%. Effective June 30, 2026, the Group obtained control, transitioning the entity from an associate to a subsidiary consolidated on a line-by-line basis under Ind AS 103 and Ind AS 110.

As part of the step acquisition accounting under Ind AS 103:

-Goodwill of ₹914.64 million and Non-Controlling Interest (NCI) of 45.51% were recognized.
-The previously held 48.20% equity interest was remeasured at fair value on June 30, 2026.

9 On May 14, 2026, the Group acquired 100% equity in ARAI Solutions Private Limited (a healthcare AI provider) for a cash consideration of ₹110.00 million. The business combination is accounted for under Ind AS 103, and ARAI is consolidated from the acquisition date. Provisionally determined goodwill of ₹75.10 million represents the excess of purchase consideration over net identifiable assets acquired. The purchase price allocation is provisional pending finalization within the 12-month measurement period.

10 The consolidated financial results of the Company for the quarter and half year ended September 30, 2025 and quarter ended June 30,2026 and year ended March 31, 2026 does not include the amounts related to the acquisition of Trubridge Inc & its 5 subsidiaries and IKS WWMG MSO LLC, accordingly are not comparable to the current period.

ALI AKBAR Digitally signed by Ali Akbar Date: 2026.11.05 21:03:03 +05'30'

The statutory auditor has digitally signed the statement for identification purpose only and this statement should be read in conjuction with their report dated November 5, 2026.

For Inventurus Knowledge Solutions Limited

Nithya Balasubramanian Digitally signed by Nithya Balasubramanian Date: 2026.11.05 20:53:48 +05'30'

Nithya Balasubramanian
Whole Time Director & Chief Financial Officer
DIN - 10664861

Place : Mumbai
Date : November 5, 2026